Evidence map›Paper›PMID 18349042›Full record

ArticleBMJ (Clinical research ed.)2008

Risk of microalbuminuria and progression to macroalbuminuria in a cohort with childhood onset type 1 diabetes: prospective observational study.

Rakesh Amin, Barry Widmer, A Toby Prevost, Phillip Schwarze, Jason Cooper, Julie Edge, Loredana Marcovecchio, Andrew Neil, R Neil Dalton, David B Dunger

2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in BMJ (Clinical research ed.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 79 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 4 pooled it
9.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01581476 phase3completedstarted 2009, after this paper: background citation

Randomised, Double Blind, Placebo Controlled Trial of Angiotensin Converting Enzyme Inhibitors and Statins in the Prevention of Long Term Complications in Young People With Type 1 Diabetes

Ran2009Enrolled443Registered outcomes5Posted comparisons0ConditionsType 1 DiabetesArmsACE inhibitor, Combination therapy, Placebo, Statin
PMID 20017932PMID 22416821PMID 17257274other papers from this trial
Open the trial in the graph
NCT03835312 narecruitingnot on this mapstarted 2019, after this paper: background citation

Sequential Transplantation of Umbilical Cord Blood Stem Cells and Islet Cells in Children and Adolescents With Monogenic Immunodeficiency Type 1 Diabetes Mellitus

TypeinterventionalSponsorChildren's Hospital of Fudan UniversityRan2019 to 2030Enrolled50ConditionsDiabetes Mellitus, Type 1, Immunologic Deficiency SyndromesArmsSequential transplantation
3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 4 syntheses or guidelines pooled it, 197 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Insulin analogues in children with Type 1 diabetes: a 52-week randomized clinical trial.Diabetic medicine : a journal of the British Diabetic Association · 2013
    Trial
  6. Proteinuria in adolescence.Pediatric nephrology (Berlin, Germany) · 2026
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Rakesh AminUniversity Department of Paediatrics, Addenbrooke's Hospital, Cambridge CB2 0QQ.
Barry Widmer
A Toby Prevost
Phillip Schwarze
Jason Cooper
Julie Edge
Loredana Marcovecchio
Andrew Neil
R Neil Dalton
David B Dunger
Addenbrooke's Hospital · GBJohn Radcliffe Hospital · GBKing's College London · GBUniversity of Cambridge · GBUniversity of Oxford · GBWellcome Trust · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

objectivesTo describe independent predictors for the development of microalbuminuria and progression to macroalbuminuria in those with childhood onset type 1 diabetes.

designProspective observational study with follow-up for 9.8 (SD 3.8) years.

settingOxford regional prospective study.

participants527 participants with a diagnosis of type 1 diabetes at mean age 8.8 (SD 4.0) years.

main outcome measuresAnnual measurement of glycated haemoglobin (HbA1c) and assessment of urinary albumin:creatinine ratio.

resultsCumulative prevalence of microalbuminuria was 25.7% (95% confidence interval 21.3% to 30.1%) after 10 years of diabetes and 50.7% (40.5% to 60.9%) after 19 years of diabetes and 5182 patient years of follow-up. The only modifiable adjusted predictor for microalbuminuria was high HbA1c concentrations (hazard ratio per 1% rise in HbA1c 1.39, 1.27 to 1.52). Blood pressure and history of smoking were not predictors. Microalbuminuria was persistent in 48% of patients. Cumulative prevalence of progression from microalbuminuria to macroalbuminuria was 13.9% (12.9% to 14.9%); progression occurred at a mean age of 18.5 (5.8) years. Although the sample size was small, modifiable predictors of macroalbuminuria were higher HbA(1c) levels and both persistent and intermittent microalbuminuria (hazard ratios 1.42 (1.22 to 1.78), 27.72 (7.99 to 96.12), and 8.76 (2.44 to 31.44), respectively).

conclusionIn childhood onset type 1 diabetes, the only modifiable predictors were poor glycaemic control for the development of microalbuminuria and poor control and microalbuminuria (both persistent and intermittent) for progression to macroalbuminuria. Risk for macroalbuminuria is similar to that observed in cohorts with adult onset disease but as it occurs in young adult life early intervention in normotensive adolescents might be needed to improve prognosis.

Indexed as

AlbuminuriaAntihypertensive AgentsChildCohort StudiesDiabetes Mellitus, Type 1Disease ProgressionFemaleHumansMalePrognosisProspective StudiesAntihypertensive Agents

Identifiers

PMID18349042
PMCPMC2276285
OpenAlexW2031797041

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.